Inoviq Ltd · ASX:IIQ
Inoviq — Investor Presentation (May 2022)
32 slides from Inoviq's investor presentation, May 10, 2022
Slide 1: Investor Presentation
Investor Presentation For personal use only ASX: IIQ | 10 May 2022
Slide 2: Disclaimer
Disclaimer For personal use only This presentation has been prepared by INOVIQ Limited (“INOVIQ” or the “Company”) based on Actual results, performance or achievements could be significantly different from those expressed information available to it as at the date of this presentation. This presenta
Slide 3: Introduction
Introduction For personal use only There is a major unmet need for non-invasive, accurate and reliable diagnostic tests for cancer and other diseases. INOVIQ’s technologies enable earlier and more accurate detection - improving treatment options, patient outcomes & survival. 3 | 10 MAY 2022
Slide 4: Company overview
Company overview For personal use only INOVIQ Ltd Financial information (ASX:IIQ) • Developing diagnostic and exosome-based solutions for cancer and Ordinary shares 92,018,702 other diseases Share price (6/5/22) A$0.575 • Proprietary technology platforms for biomarker isolation and Market capitalisa
Slide 5: Unmet need for earlier cancer detection
Unmet need for earlier cancer detection For personal use only Problem 5-year survival rates by stage at diagnosis1 Cancers often diagnosed at late-stage after symptoms have 120% appeared, resulting in poor prognosis 99% 98%100% 100% 96% 93% Detection of early-stage cancers often limited by high
Slide 6: Global cancer diagnostics market
Global cancer diagnostics market For personal use only Global cancer burden is 50.6m survivors, 4.9m prevalence prevalence 7.8m 19.3m new cases and 10.0m deaths pa1 1.1m incidence $3.3b $4.2b incidence 2.3m PROSTATE BREAST Global cancer diagnostics market valued at 375k deaths CANCER CANCER deaths 6
Slide 7: Our technology platforms
Our technology platforms For personal use only INOVIQ has patented technologies and products in-market SubB2M NETs BARD1 HTERT Highly specific probe that detects the NETs platform enables the capture of Biomarker technology covering various Anti-hTERT antibody technology that pan-cancer marker Neu5G
Slide 8: Products and pipeline
Products and pipeline For personal use only ASSAY CLINICAL PRODUCT INDICATION PLATFORM USE RESEARCH DEVELOPMENT DEVELOPMENT REGISTRATION hTERT1 Bladder Cancer ICC Adjunct to cytology In-market EXO-NET-RUO Exosome Capture Device Research tool In-market Exosome-OC3 (OCRF-7) Ovarian Cancer Multiomi
Slide 9: Different uses for our tests in the diagnostic pathway
Different uses for our tests in the diagnostic pathway BEFORE DIAGNOSIS AFTER DIAGNOSIS For personal use only SCREENING DIAGNOSIS TREATMENT MONITORING SELECTION Test use Earlier detection in Aiding and confirming Staging and triage-to- Monitoring asymptomatic people diagnosis treatment treatment res
Slide 10: SubB2M | Neu5Gc specific probe
SubB2M | Neu5Gc specific probe For personal use only SubB2M: Improves specificity for cancer monitoring and detection • SubB2M detects a pan-cancer biomarker Neu5Gc found at elevated levels in multiple human cancers1 • INOVIQ holds the exclusive worldwide licence to SubB2M technology for diagnostic
Slide 11: SubB2M | Breast cancer performance
SubB2M | Breast cancer performance OVERALL SUBB2M SPR TEST PERFORMANCE For personal use only • POC data shows the SubB2M-based SPR test detected Breast Cancer at >95% sensitivity and 99% 100% SENSITIVITY SPECIFICITY 100% specificity across all stages (n = 118) 1,2,3 • Griffith conducted further work
Slide 12: SubB2M | Ovarian Cancer Performance
SubB2M | Ovarian Cancer Performance OVERALL SUBB2M SPR TEST PERFORMANCE For personal use only • POC data shows the SubB2M-based SPR test detected Ovarian Cancer at 100% sensitivity and 100% 100% SENSITIVITY SPECIFICITY 100% specificity across all stages (n = 69) 1,2 • Griffith conducted further work
Slide 13: SubB2M | Development plan
SubB2M | Development plan • SubB2M tests transferred to contract diagnostics organization (CDO), ResearchDx, for completion of feasibility testing and commercial assay For personal use only development1 • Assay classification and monitoring performance will be confirmed in retrospective clinical stu
Slide 14: NETs | Exosomes - like a FEDEX system for cells
NETs I Exosomes - like a FEDEX system for cells For personal use only Importance of exosomal biomarkers Exosome Structure Cells can communicate with each other by packaging messages (DNAs, RNAs, proteins & lipids) into nanovesicles (exosomes) and releasing them into biofluids (blood, saliva, urine).
Slide 15: NETs | EXO-NET exosome isolation
NETs I EXO-NET exosome isolation EXO-NET pan-exosome capture tool For personal use only • EXO-NET pan-exosome capture is a ‘research use only’ (RUO) product for isolation of exosomes from body fluids (plasma, urine and saliva) with speed, purity and yield advantages • Meets an unmet need for the rap
Slide 16: NETs | Performance of EXO-NET
NETs I Performance of EXO-NET® For personal use only EXO-NET enables fast and efficient capture of Exosomal mRNAs Exosomal Proteins exosomes from biofluids including plasma, urine and saliva EXO-NET is a proprietary and customisable multi- layered antibody matrix coated onto magnetic beads for iso
Slide 17: NETs | Exosome-based diagnostics pipeline
NETs I Exosome-based diagnostics pipeline For personal use only Collaboration with UQ1 to develop world-first “We are extremely pleased to collaborate with exosome-based ovarian cancer screening test2 Australian-based company INOVIQ to combine our innovative technologies and expertise in biomarker •
Slide 18: BARD1 | Technology and pipeline
BARD1 | Technology and pipeline For personal use only BARD1 autoantibody tests • BARD1 splice variants (proteins) are associated with cancer n formation, progression and poor prognosis Product Study (cancer:normal) AUC Sensitivity Specificity • BARD1 autoantibody (AAb) tests measure autoantibodies t
Slide 19: hTERT | ICC test for detection of hTERT
hTERT | ICC test for detection of hTERT For personal use only Anti-hTERT antibody • hTERT test is an immunocytochemistry (ICC) assay that detects hTERT • Adjunct to urine cytology to assist bladder cancer diagnosis • Registered in US (FDA Class I), Europe (CE-IVD mark), South Korea (MFDS Class II) &
Slide 20: Research to expand our IP, diagnostic opportunities and future value
Research to expand our IP, diagnostic opportunities and future value For personal use only The current market for INOVIQ’s existing product pipeline is ~$15b However…this is just the tip of the iceberg Our platforms can be applied to multiple uses and disease applications including other cancers (pr
Slide 21: Strategy & Growth Plans
Strategy & Growth Plans For personal use only 21 | 10 MAY 2022
Slide 22: INOVIQ's scalable commercialisation strategy
INOVIQ’s scalable commercialisation strategy 2 For personal use only Well trodden LDT to IVD commercialisation path Commercialise as EARLY REVENUES & INITIAL Lab Developed Tests Our strategy for commercialising MARKET ACCEPTANCE (LDT) diagnostics implements a risk-based LDT to IVD dual commercialisa
Slide 23: Achievements and catalysts
Achievements and catalysts For personal use only 1Q 2022 2Q 2022 3Q 2022 4Q 2022 2023 EXO-NET collaborations SubB2M - New EXO-NET Secure LDT laboratory - SubB2M BC test results (AU) assay development collaborations partner - SubB2M OC test results SubB2M manufacturing (ResearchDx) - EXO-NET
Slide 24: Why invest?
Why invest? For personal use only Innovative Patented Strong Compelling Company Technology Pipeline Results 1 2 3 4 Focused on diagnostic and Proprietary biomarker Multi-product pipeline Early data for SubB2M and exosome-based solutions to isolation & detection for detection of common exosome-based
Slide 25: Contacts
Contacts For personal use only INOVIQ Ltd 23 Normanby Road Dr Leearne Hinch Notting Hill VIC 3168 Chief Executive Officer Australia e. lhinch@inoviq.com m. +61 400 414 416 p. +61 3 9548 7586 e. info@inoviq.com w. www.inoviq.com 25 | 10 MAY 2022
Slide 26: Appendices
Appendices For personal use only 26 | 10 MAY 2022
Slide 27: Difference between SubB2M and exosome-based OC tests
Difference between SubB2M and exosome-based OC tests For personal use only Product development is being driven via our SubB2M and EXO-NET platforms SubB2M-based tests: improve the performance Exosome-based tests: new multi-marker tests for earlier of existing biomarker tests and more accurate detect
Slide 28: Extracellular vesicle Isolation Methods
Extracellular vesicle Isolation Methods For personal use only • EXO-NET is an immunomagnetic bead capture technology 28 | 10 MAY 2022
Slide 29: EXO-NET | Workflow for exosome capture
EXO-NET | Workflow for exosome capture For personal use only • EXO-NET isolates exosomes from body fluids within 15 minutes for downstream analysis of exosomal biomarkers (proteins, RNAs, lipids) • Suitable for high throughput screening of exosomes • Enabling tool for exosome-based diagnostics B C D
Slide 30: Strong patent portfolio
Strong patent portfolio For personal use only • Broad patent portfolio Patent Family Title Granted Pending Expiry protecting IIQ’s core SubB2M biomarker isolation and BR, CA, CN, PCT/AU2017/051230 (WO 2018/085888) Subtilase cytotoxin B subunit mutant AU EP, IN, JP, 2037 detection technologies, KR, U
Slide 31: Healthcare Experienced Board
Healthcare Experienced Board For personal use only DR GEOFF CUMMING PhD MAX JOHNSTON PHILIP POWELL Prof ALLAN CRIPPS AO PhD Non-Executive Chairman Non-Executive Director Non-Executive Director Non-Executive Director Healthcare and biotechnology director with Healthcare industry director and internat
Slide 32: Management
Management For personal use only DR LEEARNE HINCH DR GREG RICE PhD TONY DI PIETRO Dr ROCCO IANNELLO Chief Executive Officer Chief Scientific Officer CFO & Company Secretary Business Development and Licensing Director An experienced biotechnology executive and life An internationally recognised scien